The outcomes of favipiravir exposure in pregnancy: a case series.
Archives of gynecology and obstetrics, cilt.307, sa.1, ss.1385-1395, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 307 Sayı: 1
- Basım Tarihi: 2023
- Doi Numarası: 10.1007/s00404-022-06615-z
- Dergi Adı: Archives of gynecology and obstetrics
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.1385-1395
- Anahtar Kelimeler: Favipiravir, Pregnancy outcomes, Teratogen
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Dokuz Eylül Üniversitesi Adresli: Evet
Özet
Purpose As in vitro and in vivo studies reported antiviral efficacy against RNA viruses, favipiravir, a pyrazinecarboxamide derivative, has become one of the treatment options for COVID-19 in some countries including Turkey. Preclinical studies demonstrated the risk for teratogenicity and embryotoxicity. Hence, the drug is contraindicated during pregnancy. Although limited in numbers, case-based evaluations indicate that favipiravir might not be a major teratogen in human pregnancies. This study aimed to present and analyze the outcomes of favipiravir exposure during pregnancy.